PT  - JOURNAL ARTICLE
AU  - Kunze, Katie L.
AU  - Johnson, Patrick W.
AU  - van Helmond, Noud
AU  - Senefeld, Jonathon W.
AU  - Petersen, Molly M.
AU  - Klassen, Stephen A.
AU  - Wiggins, Chad C.
AU  - Klompas, Allan M.
AU  - Bruno, Katelyn A.
AU  - Mills, John R.
AU  - Theel, Elitza S.
AU  - Buras, Matthew R.
AU  - Golafshar, Michael A.
AU  - Sexton, Matthew A.
AU  - Soto, Juan C. Diaz
AU  - Baker, Sarah E.
AU  - Shepherd, John R.A.
AU  - Verdun, Nicole C.
AU  - Marks, Peter
AU  - Paneth, Nigel S.
AU  - Fairweather, DeLisa
AU  - Wright, R. Scott
AU  - Casadevall, Arturo
AU  - Carter, Rickey E.
AU  - Joyner, Michael J.
AU  - ,
AU  - van Buskirk, Camille M.
AU  - Winters, Jeffrey L.
AU  - Stubbs, James R.
AU  - Senese, Katherine A.
AU  - Pletsch, Michaela C.
AU  - Buchholtz, Zachary A.
AU  - Rea, Robert F.
AU  - Herasevich, Vitaly
AU  - Whelan, Emily R.
AU  - Clayburn, Andrew J.
AU  - Larson, Kathryn F.
AU  - Ripoll, Juan G.
AU  - Andersen, Kylie J.
AU  - Lesser, Elizabeth R.
AU  - Vogt, Matthew N.P.
AU  - Dennis, Joshua J.
AU  - Regimbal, Riley J.
AU  - Bauer, Philippe R.
AU  - Blair, Janis E.
TI  - Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors
AID  - 10.1101/2021.03.19.21253975
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.19.21253975
4099  - http://medrxiv.org/content/early/2021/04/02/2021.03.19.21253975.short
4100  - http://medrxiv.org/content/early/2021/04/02/2021.03.19.21253975.full
AB  - Successful therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have harnessed the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Evidence that SARS-CoV-2 exists as locally evolving variants suggests that immunological differences may impact the effectiveness of antibody-based treatments such as convalescent plasma and vaccines. Considering that near-sourced convalescent plasma is likely to reflect the antigenic composition of local viral strains, we hypothesized that convalescent plasma has a higher efficacy, as defined by death within 30 days of transfusion, when the convalescent plasma donor and treated patient were in close geographic proximity. Results of a series of modeling techniques applied to a national registry of hospitalized COVID-19 patients supported this hypothesis. These findings have implications for the interpretation of clinical studies, the ability to develop effective COVID-19 treatments, and, potentially, for the effectiveness of COVID-19 vaccines as additional locally-evolving variants continue to emerge.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project has been funded in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority under Contract No. 75A50120C00096. Additionally, this study was supported in part by National Center for Advancing Translational Sciences (NCATS) grant UL1TR002377, National Heart, Lung, and Blood Institute (NHLBI) grant 5R35HL139854 (to MJJ) and grant 1F32HL154320 (to JWS), Natural Sciences and Engineering Research Council of Canada (NSERC) PDF-532926-2019 (to SAK), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 5T32DK07352 (to CCW), National Institute of Allergy and Infectious Disease (NIAID) grants R21 AI145356, R21 AI152318 and R21 AI154927 (to DF), R01 AI152078 9 (to AC), National Heart Lung and Blood Institute RO1 HL059842 (to AC), National Institute on Aging (NIA) U54AG044170 (to SEB), Schwab Charitable Fund (Eric E Schmidt, Wendy Schmidt donors), United Health Group, National Basketball Association (NBA), Millennium Pharmaceuticals, Octapharma USA, Inc, and the Mayo Clinic.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Mayo Clinic institutional review board (IND 19832 Sponsor: Dr. Michael J. Joyner, MD). Written informed consent was obtained from the patients, from legally authorized representatives of the patients, or by means of an emergency consent process if necessary.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData not available.